Offering Structured to Accelerate Streamex's Operational Build-Out, Strategically Allocated with No Warrants Offering Structured to Accelerate Streamex's Operational Build-Out, Strategically Allocated with No Warrants

NEW YORK , Aug. 15, 2025 /PRNewswire/ -- FanDuel, North America's premier online gaming company, today announced a new market access agreement with St. Louis CITY SC. The partnership comes ahead of the launch of mobile sports betting in Missouri.

Gold is closing the week on a defensive note, testing key support levels within a tightening consolidation. A test of lower boundary as support may be approaching.

Ness Ziona, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced today that it plans to conduct a reverse share split of the Company's outstanding ordinary shares, no par value per share, at a ratio of 1-for-7 which is expected to be implemented at market open on the Tel-Aviv Stock Exchange on August 24, 2025 and on the Nasdaq Capital Market on August 25, 2025.

Guangzhou, China, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Youxin Technology Ltd (Nasdaq: YAAS) (the “Company” or “Youxin Technology”), a software as a service (“SaaS”) and platform as a service (“PaaS”) provider committed to helping retail enterprises digitally transform their businesses, today announced that it received two staff determination notices (the “Notice(s)”) from the Listings Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on August 13, 2025. The Notices notify the Company that it is not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, and pursuant to …

NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

Energy has experienced a 0.85% loss, making it the second-worst performer among the 11 sectors of the S&P 500 this year. Much of that is attributable to the oil majors' lackluster performances in 2025.

Brinker International's turnaround, led by Chili's, has driven exceptional sales and margin growth, outperforming industry peers and boosting earnings significantly. Management's focus on operational efficiency, menu innovation, and labor utilization has sustained profit growth despite food inflation and industry headwinds. Maggiano's turnaround is underway, leveraging Chili's successful strategies, offering additional upside if management executes as planned.

DUBLIN, Ohio , Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025.

Lauded for their yield, credit quality, and of course, their federal tax-free income, municipal bond benefits are also extending into the containment of tariff contagion. A pair of funds that income investors should consider are the Vanguard Tax-Exempt Bond ETF (VTEB) and the Vanguard Core Tax-Exempt Bond ETF (VCRM).

The S&P 500 notched three new record highs this week but the rally fell short on Friday. The index ultimately finished the week up 0.9%, its fourth weekly gain in the past five weeks.

The yield on the 10-year note ended August 15, 2025 at 4.33%. Meanwhile the 2-year note ended at 3.75% and the 30-year note ended at 4.92%.

Sen. Josh Hawley (R-MO) said he intends to investigate whether Meta's generative AI products exploit, deceive, or harm children, after leaked internal documents showed the company's chatbots were allowed to have “romantic” and “sensual” chats with children.

The FDA's approval and commercial launch of Abeona Therapeutics Inc.'s Zevaskyn for RDEB, plus $155M PRV sale, provides strong financial runway for company for two years. AIM AAV204 capsid platform and ABO-503 gene therapy offer differentiated potential in rare eye disorders, with key catalysts in 2025-2026. ABEO expansion opportunities exist via licensing deals, notably with Beacon Therapeutics, and broader application of the AIM capsid library towards other indications.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about the company's latest milestone: dosing the first patient in its Phase 2a clinical trial targeting multiple system atrophy (MSA), a rare and fatal neurodegenerative condition with no approved treatment. Elrifi explained the trial involves the company's investigational monoclonal antibody, Foralumab, which is administered intranasally and aims to reduce neuroinflammation.

Company Intends to Use Net Proceeds to Fund Purchase of Bitcoin and for General Corporate Purposes Follows the Completion of KindlyMD's Merger with Nakamoto to Form Institutional-Grade Bitcoin Treasury Vehicle SALT LAKE CITY, UT / ACCESS Newswire / August 15, 2025 / KindlyMD, Inc. (NASDAQ:NAKA) ("KindlyMD" or the "Company"), a provider of integrated healthcare services and institutional-grade Bitcoin treasury vehicle, today announced that it has closed its previously announced offering of a senior secured convertible note in an aggregate principal amount of $200.0 million (the "Convertible Note") in a private offering to YA II PN, Ltd., an investment fund managed …

Dillard's was able to crush Q2 EPS expectations on Thursday thanks to its operational efficiency, modest sales growth, and shareholder-friendly capital allocation.

- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP ® companion diagnostic - Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025.

CHICAGO--(BUSINESS WIRE)--OFS Credit Company, Inc. (Nasdaq: OCCI) (“OFS Credit”, the “Company”, “we”, “us” or “our”), an investment company that primarily invests in collateralized loan obligation (“CLO”) equity and debt securities, today announced the following net asset value (“NAV”) estimate at July 31, 2025. Management's unaudited estimate of the range of our NAV per share of our common stock at July 31, 2025 is between $6.08 and $6.18. This estimate is not a comprehensive statement of our.

New York, United States, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Graphjet Technology (NADSAQ: GTI) (the “Company”) today announced that its board of directors (the “Board”) has determined the effective date for the previously approved share consolidation of the Company's ordinary shares at a ratio of 1-for-60 and to reduce the par value of the Company's ordinary shares from $0.0001 per share to $0.006 per share (the “Share Consolidation”). The Share Consolidation will become effective as of 12:01 a.m.